| Literature DB >> 33212878 |
Ilona Górna1, Marta Napierala2, Ewa Florek2.
Abstract
The metabolic syndrome is a combination of several metabolic disorders, such as cardiovascular disease, atherosclerosis, and type 2 diabetes. Lifestyle modifications, including quitting smoking, are recommended to reduce the risk of metabolic syndrome and its associated complications. Not much research has been conducted in the field of e-cigarettes and the risk of metabolic syndrome. Furthermore, taking into account the influence of e-cigarettes vaping on the individual components of metabolic syndrome, i.e, abdominal obesity, insulin resistance, dyslipidemia and elevated arterial blood pressure, the results are also ambiguous. This article is a review and summary of existing reports on the impact of e-cigarettes on the development of metabolic syndrome as well as its individual components. A critical review for English language articles published until 30 June 2020 was made, using a PubMed (including MEDLINE), Cochrane, CINAHL Plus, and Web of Science data. The current research indicated that e-cigarettes use does not affect the development of insulin resistance, but could influence the level of glucose and pre-diabetic state development. The lipid of profile an increase in the TG level was reported, while the influence on the level of concentration of total cholesterol, LDL fraction, and HDL fraction differed. In most cases, e-cigarettes use increased the risk of developing abdominal obesity or higher arterial blood pressure. Further research is required to provide more evidence on this topic.Entities:
Keywords: dyslipidemia; electronic cigarettes; insulin resistance; metabolic syndrome; obesity
Year: 2020 PMID: 33212878 PMCID: PMC7711672 DOI: 10.3390/toxics8040105
Source DB: PubMed Journal: Toxics ISSN: 2305-6304
Search strategy.
| Objectives |
To assess the contribution of existing literature of association of electronic cigarette use and metabolic syndrome development as well as its individual components (insulin resistance, diabetes, dyslipidemia, obesity, blood pressure). To compare the impact of e-cigarettes use and smoking conventional cigarettes on metabolic syndrome To identify relevant information and outline existing knowledge To identify any gap in the existing research |
| Research question |
Does electronic cigarette use have a significant impact on metabolic syndrome development? Does electronic cigarette use have a significant impact on the occurrence of metabolic syndrome components (insulin resistance, diabetes, dyslipidemia, obesity, blood pressure)? |
| Keywords |
“electronic cigarettes” or “tobacco smoking” and “metabolic syndrome”; “electronic cigarettes” or “tobacco smoking” and “insulin resistance”; “electronic cigarettes” or “tobacco smoking” and “diabetes”; “electronic cigarettes” or “tobacco smoking” and “dyslipidemia”; “electronic cigarettes” or “tobacco smoking” and “obesity”; “electronic cigarettes” or “tobacco smoking” and “blood pressure” |
The impact of electronic cigarettes use and tobacco smoke exposure on MetS.
| Type of Study | Participants/Rodents/Type of Cells | Country | Exposure Assessment | Results | Reference |
|---|---|---|---|---|---|
|
| |||||
| Human | Participants of the constancies cohort | France | Questionnaire | Lequy et al. [ | |
| Human | Male participants ( | Republic of Korea | Urinary cotinine | Kim et al. [ | |
| Human | Participants | Republic of Korea | Questionnaire | Oh et al. [ | |
|
| |||||
| In vitro-cells | Mouse embryo 3T3-L1 pre-adipocytes (ATCC®CL-173™, ATCC, Manassas, VA, USA). | United States | Exposure to cigarette smoke, electronic cigarettes, and heated tobacco products. | Zagoriti et al. [ | |
| Animal | Male Wistar rats (young adults). | Jordan | Exposure to waterpipe tobacco smoke. | Al-Sawalha et al. [ | |
| Human | Male participants | Japan | Questionnaire | Matsushita et al. [ | |
| Human | Participants | United States | Questionnaire | Yankey et al. [ | |
| Human | Participants | Venezuela | Questionnaire | Bermudez et al. [ | |
| Human | Participants | Taiwan | Questionnaire | Lin et al. [ | |
| Human | Participants | Chile | Questionnaire | Cheng et al. [ | |
| Human | Participants | Colombia | Questionnaire | Barranco-Ruiz et al. [ | |
The impact of electronic cigarettes use and tobacco smoke exposure on insulin resistance and diabetes.
| Type of Study | Participants/Rodents/Type of Cells | Country | Exposure Assessment | Results | Reference |
|---|---|---|---|---|---|
|
| |||||
| Animal | C57BL6/J mice | United States | Exposure to e-cigarette aerosol or mainstream cigarette smoke comparable with filtered air-exposed controls. | Orimoloye et al. [ | |
| Animal | Male Wistar rats | Tunisia | E-liquid with or without nicotine and nicotine alone (0.5 mg/kg of body weight) were administered intraperitoneally during 28 days. | El Goli et al. [ | |
| Human | Participants | United States | Questionnaire | Atuegwu et al. [ | |
| Human | Male participants | Republic of Korea | Urinary cotinine | Kim et al. [ | |
|
| |||||
| Animal | Male C57BL/6J mice (8 week old). | China | Low dosages of nicotine (0.8 mg/kg/d), high dosages of nicotine (4 mg/kg/d), or saline (vehicle) using Alzet osmotic pumps. | Wu et al. [ | |
| Human | Participants | Multi- Ethnic Study | Self-reported tobacco status and reclassified by urinary cotinine. | Keith et al. [ | |
| Human | Participants | Sweden | Nicotine 0.3 µg/kg/min or NaCl was infused (2 h) during a euglycemic hyperinsulinemia clamp (4 h). | Axelsson et al. [ | |
| Human | Review—25 prospective cohort studies. | Willi et al. [ | |||
| Human | Participants | United States | Questionnaire | Yankey et al. [ | |
The impact of electronic cigarettes use and tobacco smoke exposure on dyslipidemia.
| Type of Study | Participants/Rodents/Type of Cells | Country | Exposure Assessment | Results | Reference |
|---|---|---|---|---|---|
|
| |||||
| Animal | Male Wistar rats | Tunisia | E-liquid with or without nicotine and nicotine alone (0.5 mg/kg of body weight) administered intraperitoneally during 28 days. | El Goli et al. [ | |
| Animal | Male adult C57BL/6J | United States | Exposed to saline or e-cigarettes with 2.4% nicotine aerosol for 12 weeks. | Hasan et al. [ | |
| Human | Participants ( | Romania | Self-reports of the participants. | Badea et al. [ | |
|
| |||||
| Animal | The human CETP transgenic mice (C57BL/6) | China | Exposure to either room air or cigarette smoke at five cigarettes/d and 5 d/wk for 12 weeks | Zong et al. [ | |
| Animal | Male C57BL/6J mice | China | Low dosages of nicotine (0.8 mg kg−1 d−1), high dosages of nicotine (4 mg kg−1 d−1), or saline (vehicle) using Alzet osmotic pumps | Wu et al. [ | |
| Human | Review | Athyros et al. [ | |||
| Human | Participants | United States | Questionnaire | Yankey et al. [ | |
The impact of electronic cigarettes use and tobacco smoke exposure on abdominal obesity.
| Type of Study | Participants/Rodents/Type of Cells | Country | Exposure Assessment | Results | Reference |
|---|---|---|---|---|---|
|
| |||||
| In vitro-cells | Mouse embryo 3T3-L1 pre-adipocytes (ATCC®CL-173™, ATCC, Manassas, VA, USA). | United States | Exposure to cigarette smoke, electronic cigarettes and heated tobacco products. | Zagoriti et al. [ | |
| Animal | Male Wistar rats | Tunisia | E-liquid with or without nicotine and nicotine alone (0.5 mg/kg of body weight) were administered intraperitoneally during 28 days. | El Goli et al. [ | |
| Animal | Neonatal C57BL/6J mice | United States | Exposure to e-cigarettes for the first 10 days of life; e-cigarette cartridges contained either 1.8% nicotine in propylene glycol (PG) or PG vehicle alone; plasma and urine cotinine measurements. | McGrath-Morrow et al. [ | |
| Animal | Male BALB/cJ mice (Charles River, Calco, Como), 183 month-old. | Italy | Exposure to the smoke of 21 cigarettes or e- cigarette vapor containing 16.8 mg of nicotine delivered by means of a mechanical ventilator for three 30-min sessions/day for seven weeks. | Ponzoni et al. [ | |
| Animal | Male and female Sprague–Dawley rats | United States | Exposure to low-, mid- and high-dose levels of aerosols composed of vehicle (glycerin and propylene glycol mixture); vehicle and 2.0% nicotine; or vehicle, 2.0% nicotine and flavor mixture; plasma nicotine and cotinine and carboxyhemoglobin levels. | Werley et al. [ | |
| Human | Male participants | Republic of Korea | Urinary cotinine | Kim et al. [ | |
| Human | Participants | Italy | Questionnaire | Polosa et al. [ | |
| Human | Participants | United States | Questionnaire | Delk et al. [ | |
|
| |||||
| Animal | Female and male Sprague Dawley OFA rat. | Switzerland | Nicotine or saline was infused subcutaneously via Alzet osmotic mini-pumps; cotinine and other principal metabolites of nicotine in the serum. | Somm et al. [ | |
| Animal | Participants | Finland | Questionnaire | Molarius et al. [ | |
| Human | Male participants | United States | Questionnaire | Shimokata et al. [ | |
| Human | Participants | United States | Questionnaire | Barrett-Connor et al. [ | |
| Human | Participants | Sweden | Questionnaire | Lissner et al. [ | |
| Human | Participants | Netherlands | Questionnaire | Visser et al. [ | |
| Human | Participants | Scotland | Questionnaire | Akbartabartoori et al. [ | |
| Human | Participants | Switzerland | Questionnaire | Clair et al. [ | |
| Human | Participants | China | Questionnaire | Lv et al. [ | |
The impact of electronic cigarettes use and tobacco smoke exposure on arterial hypertension.
| Type of Study | Participants/Rodents/Type of Cells | Country | Exposure Assessment | Results | Reference |
|---|---|---|---|---|---|
|
| |||||
| Human | Participants | United States | Questionnaire, plasma cotinine | Moheimani et al. [ | |
| Human | Participants | Italy | Questionnaire | Polosa et al. [ | |
| Human | Participants | United States | Two commercial products that contain 16 mg/mL (1.6%) nicotine and three non-commercial products that contain 24 mg/mL (2.4%) nicotine, in the cartomizer device format attached to rechargeable batteries. In comparison Marlboro Gold King Size 0.8 mg per cigarette. | Yan et al. [ | |
| Human | Participants | Greece | Commercially-available tobacco cigarette: nicotine (1.0 mg), tar (10 mg) and carbon monoxide (10 mg) yields, and electronic cigarette, commercially-available device, with liquid containing 11 mg/mL nicotine concentration. | Farsalinos et al. [ | |
| Human | Participants | Greece | 4 separate occasions (total 96 sessions): (1) tobacco cigarette over 5 min; (2) e-cigarette over 5 min; (3) e-cigarette for a period of 30 min and (4) nothing (sham procedure) for 60 min. | Vlachopoulos et al. [ | |
| Human | Participants | Germany | (1) Smoking a cigarette and inhaling into the lungs, (2) Vaping an e-cigarette with nicotine and (3) Vaping an e-cigarette without nicotine. | Franzen et al. [ | |
| Human | Participants | Sweden | The e-liquid base consisted primarily of 49.4% propylene glycol, 44.4% vegetable glycerin, and 5% ethanol without any added flavorings. Premixed e-liquids with and without added nicotine were used (19 mg/mL and 0 mg/mL resp). Inhaled 30 puffs from the e-cigarette for 30 min, with each puff lasting approximately three seconds. | Antoniewicz et al. [ | |
| Human | Participants | United States | E-cigarette-users after using an e-cigarette with nicotine, e-cigarette without nicotine, nicotine inhaler, or sham-vaping (control); nicotine and cotinine plasma levels. | Arastoo et al. [ | |
| Human | Participants who were willing to quit smoking | United Kingdom | E-cigarette containing 16 mg nicotine or nicotine-free e-cigarette plus nicotine flavoring. | George et al. [ | |
| Human | Participants who were willing to quit smoking | Greece | E-cigarette kit with “Original” (2.4% nicotine—Group A), or “Categoria” (1.8% nicotine—Group B), or “Original” without nicotine (“sweet tobacco” aroma—Group C) cartridges. | Farsalinos et al. [ | |
|
| |||||
| Human | Participants | United States | Two commercial products that contain 16 mg/mL (1.6%) nicotine and three non-commercial products that contain 24 mg/mL (2.4%) nicotine, in the cartomizer device format attached to rechargeable batteries. In comparison to Marlboro Gold King Size 0.8 mg per cigarette. | Yan et al. [ | |
| Human | Participants | Venezuela | Questionnaire | Increase of blood pressure compared with nonsmokers, | Bermudez et al. [ |